Digital Content 
NEWS #PharmaBuzz
13 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/13/3132962/0/en/BioVie-Highlighted-ADDRESS-LC-Phase-2-Trial-Design-Exploring-Bezisterim-for-the-Treatment-of-Neurological-Symptoms-of-Long-COVID-at-Keystone-Symposia-on-Long-COVID-and-Other-Post-A.html
24 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/24/3120972/0/en/BioVie-Presented-Data-Highlighting-that-Patients-Treated-with-Bezisterim-Potentially-Experienced-an-Age-Deceleration-Advantage-Compared-to-Placebo-on-10-Different-Biological-Clocks.html
09 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/09/3112501/0/en/BioVie-Announces-Data-Highlighting-Bezisterim-s-Potential-to-Slow-or-Reverse-Biological-Aging-and-Neurodegeneration-Featured-as-a-Keynote-Talk-at-the-7th-World-Aging-and-Rejuvenati.html
15 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/15/3082114/0/en/BioVie-Enrolls-First-Patient-in-ADDRESS-LC-Clinical-Trial-Assessing-Novel-Anti-Inflammatory-Candidate-Bezisterim-for-the-Treatment-of-Neurological-Symptoms-Associated-with-Long-COV.html
16 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/16/3062472/0/en/BioVie-Initiates-SUNRISE-PD-Clinical-Trial-Assessing-Bezisterim-in-Early-Parkinson-s-Disease-with-First-Patient-Enrolled.html
20 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/20/2984379/0/en/BioVie-to-Present-Design-of-Planned-Phase-2-Study-of-Bezisterim-for-the-Treatment-of-Long-COVID-at-the-Demystifying-Long-COVID-International-Conference.html
Share 